UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/17.12.25 | Real-time BOERSE MUENCHEN 09:40:05 2024-05-20 am EDT | ||
| 4.04 EUR | -0.98% |
|
| Current month | +70.71% | ||
| 1 month | +46.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-20 | 4.04 | -0.98% |
| 24-05-17 | 4.08 | +6.53% |
| 24-05-16 | 3.83 | +1.59% |
| 24-05-15 | 3.77 | +10.88% |
| 24-05-14 | 3.4 | -3.13% |
Real-time BOERSE MUENCHEN
Last update May 20, 2024 at 09:40 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD1R1B |
| ISIN | DE000HD1R1B9 |
| Date issued | 2024-01-08 |
| Strike | 550 $ |
| Maturity | 2025-12-17 (576 Days) |
| Parity | 10 : 1 |
| Emission price | 4.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.57 € |
|---|---|
| Lowest since issue | 2.36 € |
| Spread | 0.1 € |
| Spread % | 2.41% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Warrants
- Warrant
